Journal
TRENDS IN MOLECULAR MEDICINE
Volume 21, Issue 4, Pages 223-232Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2015.01.001
Keywords
nanomedicine; targeted delivery; combination therapy; cancer
Funding
- National Institutes of Health (NIH) [CA151884]
- National Heart, Lung, and Blood Institute (NIH) [HHSN268201000045C]
- David Koch-Prostate Cancer Foundation Award in Nanotherapeutics
- NIH National Research Service Award (NRSA) [1F32CA168163-03]
- Canadian Institutes of Health Research (CIHR)
Ask authors/readers for more resources
The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer. The unique properties of nanoparticles (NPs), such as large surface-to-volume ratio, small size, the ability to encapsulate various drugs, and tunable surface chemistry, give them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies. This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available